Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000302
Chunk: 56

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 56
---
| 41 |

| 87 | OVERSEAS REGISTERS |

Subject to the Companies Acts and
the Uncertificated Securities Regulations, the Board may exercise the powers conferred on the Company with regard to the keeping of an
overseas branch, local or other register in relation to members and may make and vary such regulations as it thinks fit concerning the
keeping of any such register.

| 88 | ASSOCIATE DIRECTORS |

The Board may appoint any person (not
being a Director) to any office or employment having a designation or title including the word “director” or attach
to any existing office or employment with the Company such designation or title and may terminate any such appointment or the use of such
designation or title. The inclusion of the word “director” in the designation or title of any such office or employment
shall not imply that such person is, or is deemed to be, or is empowered in any respect to act as, a Director for any of the purposes
of the Companies Acts or these Articles.

| 89 | BORROWING POWERS |

| 89.1 | Subject to this Article 89, the Board may exercise all the powers of the Company to borrow money and to                                      
 mortgage or charge all or part of the undertaking, property and assets (present or future) and uncalled capital of the Company and, subject  
 to the Companies Acts, to create and issue debentures and other securities, whether outright or as collateral security for a debt, liability 
 or obligation of the Company or of a third party.                                                                                            |

| 89.2 | The Board shall restrict the borrowings of the Company and shall exercise all voting and other rights                                           
 or powers of control exercisable by the Company in relation to its subsidiary undertakings so as to ensure (as regards subsidiary undertakings, 
 to the extent possible by such exercise) that the aggregate of the amounts borrowed by the Group and remaining outstanding at any time          
 (excluding intra Group borrowings) shall not without the previous sanction of an ordinary resolution of the Company exceed an amount equal      
 to two times the gross asset value of the Group where gross asset value is defined as total fixed plus total current assets as measured         
 under UK GAAP or total current plus total non-current assets as measured under IFRS as appropriate provided always that no such sanction        
 shall be required to the borrowing of any moneys intended to be applied and actually applied within six months in the repayment (with           
 or without premium